Lee Ainslie Ultragenyx Pharmaceutical Inc. Transaction History

Maverick Capital LTD

  • $5.84 Billion
  • Q2 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$73.71 - $87.86 $432,014 - $514,947
-5,861 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$77.92 - $102.4 $335,913 - $441,446
-4,311 Reduced 42.38%
5,861 $529,000
Q2 2021

Aug 16, 2021
SELL
$92.19 - $115.71 $92,282 - $115,825
-1,001 Reduced 8.96%
10,172 $970,000
Q1 2021

May 17, 2021
BUY
$106.9 - $167.73 $1.19 Million - $1.87 Million
11,173 New
11,173 $1.27 Million

Others Institutions Holding RARE

# of Institutions
365
Shares Held
88.1M
Call Options Held
3.64M
Put Options Held
2.24M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.2B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email